Voyager Therapeutics is a gene therapy company developing treatments for fatal and debilitating diseases of the central nervous system (CNS). It is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia.

Voyager Therapeutics is dedicated to developing life-changing gene therapies for patients suffering from severe neurological diseases. Their core mission revolves around harnessing the power of adeno-associated virus (AAV) gene therapy to target and treat debilitating conditions, such as Parkinson's disease, Huntington's disease, and ALS. By leveraging their expertise in AAV technology and neuroscience, Voyager Therapeutics aims to bring hope and improve the quality of life for patients and their families, ultimately transforming the landscape of neurological care.

• For specific information about our perks and employee benefits at Voyager, please visit our website to learn more

• Patient focus: Voyager Therapeutics is dedicated to improving the lives of patients, with a focus on developing transformative gene therapies for severe neurological diseases.
• Scientific rigor: Voyager Therapeutics upholds the highest standards of scientific rigor, with a commitment to advancing gene therapy research through rigorous experimentation and data analysis.
• Collaboration: Collaboration is key to Voyager Therapeutics' success, with a focus on fostering partnerships and teamwork to accelerate the development of gene therapies.
• Innovation: Voyager Therapeutics is driven by a culture of innovation, encouraging employees to think creatively and push the boundaries of gene therapy development.